Breaking News

Tweet TWEET

Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

  Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire

LEXINGTON, Mass. -- November 12, 2013

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it has
commenced an underwritten public offering of shares of its common stock. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering.

Jefferies LLC is acting as the sole book-running manager for the proposed
offering.

The securities described above are being offered by Synta pursuant to a shelf
registration statement that was previously filed with and declared effective
by the Securities and Exchange Commission (SEC). This press release does not
constitute an offer to sell or a solicitation of an offer to buy the
securities in this offering, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. A preliminary
prospectus supplement related to the offering will be filed with the SEC and
will be available on the SEC's website located at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus relating to
this offering may be obtained by sending a request to: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th
Floor, New York, NY, 10022, by telephone at 877-547-6340, or by email at
Prospectus_Department@Jefferies.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities.

Safe Harbor Statement

This media release contains forward-looking statements about Synta
Pharmaceuticals Corp., including statements relating to the proposed public
offering of securities. Such statements are based on assumptions and subject
to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements,
including those described in "Risk Factors" of the preliminary prospectus
supplement related to the offering, as filed with the Securities and Exchange
Commission. Synta undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or otherwise,
except as required by law.

Contact:

Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com